In a filing, Krystal Biotech Inc revealed its President, R&D Krishnan Suma unloaded Company’s shares for reported $4.44 million on Mar 13 ’25. In the deal valued at $177.79 per share,25,000 shares were sold. As a result of this transaction, Krishnan Suma now holds 1,533,056 shares worth roughly $211.88 million.
Then, Krishnan Suma sold 25,000 shares, generating $4,444,761 in total proceeds. Upon selling the shares at $177.79, the President, R&D now owns 1,463,711 shares.
Before that, Krishnan Krish S sold 25,000 shares. Krystal Biotech Inc shares valued at $4,444,763 were divested by the President and CEO at a price of $177.79 per share. As a result of the transaction, Krishnan Krish S now holds 1,533,056 shares, worth roughly $211.88 million.
Jefferies initiated its Krystal Biotech Inc [KRYS] rating to a Buy in a research note published on March 05, 2025; the price target was $245. A number of analysts have revised their coverage, including Citigroup’s analysts, who decreased its forecast for the stock in early August from “a Buy” to “a Neutral”. Goldman began covering KRYS with “Buy” recommendation on November 20, 2023. Cantor Fitzgerald started covering the stock on October 24, 2023. It rated KRYS as “an Overweight”.
Price Performance Review of KRYS
On Tuesday, Krystal Biotech Inc [NASDAQ:KRYS] saw its stock jump 1.57% to $138.21. Over the last five days, the stock has gained 5.58%. Krystal Biotech Inc shares have fallen nearly -11.78% since the year began. Nevertheless, the stocks have fallen -16.58% over the past one year.
How much short interest is there in Krystal Biotech Inc?
A steep rise in short interest was recorded in Krystal Biotech Inc stocks on 2025-05-15, growing by 0.18 million shares to a total of 2.6 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 2.42 million shares. There was a rise of 7.07%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 12, 2023 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $160 price target.
